In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease

Disease caused by nontuberculous mycobacteria (NTM) is increasing in frequency. The outcome of treatment for NTM lung disease is poor, particularly lung disease caused by Mycobacterium simiae and M. abscessus. Exploring synergy between active available drugs is a sensible way forward given the lack...

Celý popis

Podrobná bibliografia

Vydané v:	Antimicrobial agents and chemotherapy Ročník 56; číslo 12; s. 6324
Hlavní autori:	van Ingen, Jakko, Totten, Sarah E, Helstrom, Niels K, Heifets, Leonid B, Boeree, Martin J, Daley, Charles L
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.12.2012
Predmet:	Amikacin - pharmacology Amikacin - therapeutic use Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Clofazimine - pharmacology Clofazimine - therapeutic use Drug Synergism Microbial Sensitivity Tests Mycobacterium - drug effects Mycobacterium - growth & development Mycobacterium Infections - drug therapy Mycobacterium Infections - microbiology Nontuberculous Mycobacteria - drug effects Nontuberculous Mycobacteria - growth & development
ISSN:	1098-6596, 1098-6596
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!